Transgene SA
TRGNF
$0.85
-$0.15-15.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 159.80K | 98.80K | 37.90K | 37.90K | 1.86M |
| Total Other Revenue | 7.92M | 8.04M | 8.21M | 7.42M | 6.83M |
| Total Revenue | 8.08M | 8.14M | 8.25M | 7.46M | 6.87M |
| Cost of Revenue | 38.24M | 38.98M | 40.00M | 38.14M | 37.09M |
| Gross Profit | -30.16M | -30.84M | -31.75M | -30.68M | -30.21M |
| SG&A Expenses | 8.25M | 7.91M | 7.61M | 7.91M | 8.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.24M | 645.60K | 47.10K | 8.30K | -33.30K |
| Total Operating Expenses | 47.73M | 47.53M | 47.65M | 46.06M | 45.45M |
| Operating Income | -39.66M | -39.39M | -39.40M | -38.60M | -38.57M |
| Income Before Tax | -42.37M | -41.08M | -40.03M | -37.96M | -36.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.37 | -41.08 | -40.03 | -37.96 | -36.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.37M | -41.08M | -40.03M | -37.96M | -36.75M |
| EBIT | -39.66M | -39.39M | -39.40M | -38.60M | -38.57M |
| EBITDA | -38.16M | -37.93M | -37.96M | -37.20M | -37.19M |
| EPS Basic | -0.30 | -0.30 | -0.30 | -0.31 | -0.32 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.19 | -0.19 | -0.20 |
| EPS Diluted | -0.30 | -0.30 | -0.31 | -0.31 | -0.32 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.19 | -0.19 | -0.20 |
| Average Basic Shares Outstanding | 578.13M | 553.95M | 529.78M | 498.22M | 466.67M |
| Average Diluted Shares Outstanding | 578.13M | 553.95M | 529.78M | 498.22M | 466.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |